Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3

May 13, 2026 11:36 AM EDT News Briefing Abeona piv­ots to T cells; As­traZeneca's rare dis­ease drug pass­es Phase 3 ENDPOINTS Plus, news about Am­i­cus Ther­a­peu­tics, Fo­s­un Phar­ma, Du­al­i­ty Bio­ther­a­peu­tics, BioN­Tech and C4 Ther­a­peu­tics. 👁️ Abeona drops eye gene ther­a­pies, piv­ots to sol­id tu­mor T cell … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER